CompletedNCT01985581
Guanfacine Added to Stimulant Medication for Executive Skills in Children With ADHD
About this title
Read the official source — NCT01985581Medication studyAges 6–12Canada
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- JPM van Stralen Medicine Professional
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT01985581
- Official title
Show the full official title
A Single-Center, Randomized, Double Blind, Placebo-Controlled, Crossover Evaluation of the Effect of GXR as Adjunctive Treatment With Stimulant on Executive Function and Quality of Life at Home and School in Children With ADHD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is JPM van Stralen Medicine Professional, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Guanfacine extended release and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
